A phase 2 trial of NAB-sirolimus in patients with progressing or symptomatic epithelioid hemangioendothelioma
Active Project Grant Awarded Last action
- Award ID
- HT94252510418
- Recipient
-
Sarc UEI G9GQJWPKUZP9
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $3,238,909
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 30% complete
- Place of performance
- Ann Arbor, MI 48105, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $3,238,909 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Dana-Farber Cancer Institute, Inc. | $632,196 | |
| Mayo Clinic | $54,167 |
Quick answers
Who received award HT94252510418?
HT94252510418 was awarded to Sarc by Defense Health Agency (Department of Defense) on August 1, 2025.
How much is award HT94252510418 worth?
$3,238,909 has been obligated on HT94252510418.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award